Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus
Publication Date: February 21, 2017
Recommendations
ACP recommends that clinicians prescribe metformin to patients with type 2 diabetes when pharmacologic therapy is needed to improve glycemic control. (Moderate, Strong)
317067
ACP recommends that clinicians consider adding either a sulfonylurea, a thiazolidinedione, an SGLT-2 inhibitor, or a DPP-4 inhibitor to metformin to improve glycemic control when a second oral therapy is considered. (Moderate, Weak)
ACP recommends that clinicians and patients select among medications after discussing benefits, adverse effects, and costs.
317067
Recommendation Grading
Disclaimer
Overview
Title
Oral Pharmacologic Treatment of Type 2 Diabetes Mellitus
Authoring Organization
American College of Physicians
Endorsing Organization
American Academy of Family Physicians
Publication Month/Year
February 21, 2017
Supplemental Implementation Tools
Document Type
Guideline
External Publication Status
Published
Country of Publication
US
Inclusion Criteria
Female, Male, Adult, Older adult
Health Care Settings
Ambulatory, Hospital
Intended Users
Dietician nutritionist, diabetes educator, nurse, nurse practitioner, physician, physician assistant
Scope
Management, Treatment
Diseases/Conditions (MeSH)
D003924 - Diabetes Mellitus, Type 2
Keywords
type 2 diabetes mellitus, hyperglycemia, diabetic retinopathy, HbA1c, oral drug therapy
Supplemental Methodology Resources
Methodology
Number of Source Documents
140
Literature Search Start Date
April 1, 2009
Literature Search End Date
December 1, 2015